Molecular brakes and targets for Trop-2 in advanced prostate cancer
Official title: Molecular regulation and expression of Trop-2 in advanced prostate cancer: Identifying optimal therapeutic niches
Funded at University of Wisconsin-Madison · NIH-11369786 · Data updated 2026-11-12
A cancer-focused research grant aims to understand how Trop-2 is controlled in advanced prostate cancer to find better treatment options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $649,866 |
| NIH project number | 5R01CA276269-04 |
| Project ID | NIH-11369786 on NIH RePORTER |
Who could benefit from this research
✓Could help
Men with advanced prostate cancer, especially those whose disease has become resistant to conventional hormone- and chemotherapy-based therapies.
✕Less likely to help
Patients whose tumors do not express Trop-2 or do not exhibit the identified resistance mechanisms may not benefit from Trop-2–targeted approaches.
What this research studies
This project looks at how Trop-2, a protein on cancer cells, is regulated and expressed in advanced prostate cancer to find the best opportunities for targeted therapies. Researchers will study molecular pathways and how Trop-2 interacts with treatments to identify when therapies could be most effective. The work will involve examining tissue and blood samples from patients and using translational approaches to connect lab findings to real-world treatment challenges. The goal is to uncover specific conditions under which new therapies may work best for men with metastatic castration-resistant prostate cancer.
Why it matters
Potential benefit: If successful, the research could reveal new therapeutic windows where Trop-2–targeted treatments may improve survival and quality of life for men with advanced prostate cancer.
How similar studies have gone: Previous work has identified diverse resistance mechanisms in prostate cancer, but determining optimal Trop-2–targeted niches is an area of ongoing investigation with promising but not yet proven results.
Where this research is happening
-
University of Wisconsin-Madison
Madison, United States Active
Researchers
- Principal investigator: Lang, Joshua — University of Wisconsin-Madison
- Study coordinator: Lang, Joshua
Related research
Other NIH-funded projects on the same topics.
-
Drug that blocks tumor-made male hormones and the androgen receptor for advanced prostate cancer
A new medicine aims to block both the androgen receptor and the tumor’s own production of male hormones to help men with advanced, treatment‑resistant prostate cancer.
-
Boosting a tumor-suppressing enzyme to fight advanced prostate cancer
A research grant aims to develop new molecules that enhance the PP2A enzyme to slow or stop progression of advanced prostate cancer.
-
Modulating Androgen Signals to Boost CAR T Therapy for Prostate Cancer
A new approach uses CAR T cells targeting STEAP1 to treat advanced prostate cancer, with a focus on how androgen signals affect treatment effectiveness.
-
Genomic clues to guide therapy in advanced prostate cancer
This grant looks at how a patient’s tumor and germline DNA could predict which targeted or immune therapies will work best for advanced prostate cancer.
-
DACH1-based test to predict therapy response in advanced prostate cancer
A new test using DACH1 and other markers on prostate cancer tissue aims to predict which patients will respond to therapy and guide clinical trials.
-
Understanding how doctors choose treatments to improve advanced prostate cancer care
A clinician-researcher at Duke is exploring how medical decisions are made in advanced prostate cancer to help patients get better, fairer care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.